A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants

Summary

The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants. This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts. For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.

Timeline

Start

2026-01-06

Primary completion

2026-06

Completion

2026-06

Drugs

Indications